CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.
Killer cell immunoglobulin-like receptors in Thai patients with multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究提示 KIR 基因与 MM 保护相关，抑制性 KIR 及其配体与 MM 治疗反应相关。
自然杀伤（NK）细胞被认为参与针对多发性骨髓瘤（MM）细胞的免疫反应。杀伤细胞免疫球蛋白样受体（KIR）通过识别特定人类白细胞抗原（HLA）I 类分子配体调节 NK 细胞活性。
研究泰国人群中 KIR 基因及其配体与 MM 的关联。
研究者分析了 66 例泰国 MM 患者和 200 名健康对照者的 KIR 基因多态性及其 HLA 配体。
MM 患者中 KIR3DL1 和 2DS4 的频率显著低于对照组（P=0.02）。接受硼替佐米治疗后达到优于非常好的部分缓解（VGPR）的患者中，KIR3DL1、2DS4、携带 C2 配体的 2DL1，以及携带 Bw4 配体的 3DL1 频率显著高于仅达到 VGPR 的患者（P 分别为 0.009、0.009、0.01 和 0.02）。
研究提示 KIR 基因与 MM 保护作用相关，而抑制性 KIR 及其配体与 MM 治疗应答相关。
Natural killer (NK) cells have been implicated in the immune response against multiple myeloma (MM) cells. Killer cell immunoglobulin-like receptors (KIRs) regulate NK cell activity by recognizing specific human leukocyte antigen (HLA) class I as ligands.
To investigate the association of KIR genes and ligands with MM in the Thai population.
KIR gene polymorphisms and their HLA ligands were investigated in 66 Thai patients with MM and 200 healthy controls.
The frequencies of KIR3DL1 and 2DS4 were significantly lower in myeloma patients than in controls (P = 0.02). The frequencies of KIR3DL1, 2DS4, 2DL1 with C2, and 3DL1 with Bw4 were significantly higher in the patients achieving > very good partial response (VGPR) than those achieving VGPR after treatment with bortezomib (P = 0.009, 0.009, 0.01, and 0.02, respectively).
This study suggests the association of KIR genes with the protection against MM and the association of inhibitory KIR and ligands with the response to treatment in MM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
